Technical Analysis for NURO - NeuroMetrix, Inc.
|Grade||Last Price||% Change||Price Change|
NURO closed down 6.77 percent on Wednesday, January 16, 2019, on 1.85 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical NURO trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 16||200 DMA Support||Bullish||0.00%|
|Jan 16||Calm After Storm||Range Contraction||0.00%|
|Jan 16||Wide Range Bar||Range Expansion||0.00%|
|Jan 16||Upper Bollinger Band Walk||Strength||0.00%|
|Jan 16||Wide Bands||Range Expansion||0.00%|
|Jan 16||Overbought Stochastic||Strength||0.00%|
|Jan 16||Upper Bollinger Band Touch||Strength||0.00%|
|Jan 15||Crossed Above 200 DMA||Bullish||-6.77%|
|Jan 15||Expansion Breakout||Bullish Swing Setup||-6.77%|
|Jan 15||Pocket Pivot||Bullish Swing Setup||-6.77%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease, spinal stenosis, and diabetes. The company focuses on the diagnosis and treatment of neurological complications of diabetes, including diabetic peripheral neuropathy (DPN) and median neuropathy. Its marketed products include NC-stat DPNCheck, a device used to evaluate systemic neuropathies, such as DPN at the point-of-care; SENSUS pain therapy device, a transcutaneous electrical nerve stimulator used for chronic and intractable pain relief; and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the assesment of CTS, low back and leg pain, and DPN, as well as consumables and accessories. The company is also developing SENTINEL device that provides sensory enhancement in the feet targeted at patients who have lost sensory perception in the lower extremities. NeuroMetrix, Inc. distributes its products directly through its direct sales force and independent sales representatives to physicians, clinics, hospitals, managed care organizations, retail health businesses, and independent distributors consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons, as well as endocrinology and podiatry markets primarily in the United States, the United Kingdom, the Netherlands, and India. The company was founded in 1996 and is headquartered in Waltham, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more NURO news...
|52 Week High||2.18|
|52 Week Low||0.6|
|200-Day Moving Average||1.2172|
|50-Day Moving Average||0.932|
|20-Day Moving Average||0.8775|
|10-Day Moving Average||1.0265|
|Average True Range||0.123|
|Chandelier Exit (Long, 3 ATRs )||1.011|
|Chandelier Exit (Short, 3 ATRs )||0.969|
|Upper Bollinger Band||1.2565|
|Lower Bollinger Band||0.4985|
|Percent B (%b)||0.98|
|MACD Signal Line||0.0196|
|Market Cap||2.3 Million|
|Num Shares||1.86 Million|
|Price-to-Earnings (P/E) Ratio||-0.07|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||1.66|
|Resistance 3 (R3)||1.66||1.52||1.59|
|Resistance 2 (R2)||1.52||1.41||1.52||1.57|
|Resistance 1 (R1)||1.38||1.35||1.31||1.38||1.54|
|Support 1 (S1)||1.10||1.13||1.03||1.10||0.94|
|Support 2 (S2)||0.96||1.07||0.96||0.91|
|Support 3 (S3)||0.82||0.96||0.89|
|Support 4 (S4)||0.82|